REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $14,682 | +11.4% | 144 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $13,183 | +339.3% | 145 | +83.5% | 0.00% | – |
| Q4 2022 | $3,001 | +50.0% | 79 | +8.2% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 73 | +49.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 49 | +96.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 25 | -3.8% | 0.00% | -100.0% |
| Q3 2021 | $3,000 | -25.0% | 26 | -16.1% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | -20.0% | 31 | -36.7% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 49 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,000 | +200.0% | 49 | +145.0% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | -93.8% | 20 | -95.0% | 0.00% | -91.7% |
| Q3 2019 | $32,000 | – | 400 | – | 0.01% | – |
| Q2 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2019 | $42,000 | 0.0% | 500 | -33.3% | 0.02% | -19.0% |
| Q4 2018 | $42,000 | – | 750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |